ACTIVATED TREG FOR TOLERANCE

ACTIVATED TREG FOR TOLERANCE

WELCOME TO
ACTITREXX

At ActiTrexx we are developing novel therapies based on activated regulatory T cells (Treg). We aim to bring back tolerance to patients with dysfunctional immune system. Our goal is to tackle the root cause of autoimmune and autoinflammatory diseases, and to develop curative treatments for indications with high unmet medical need.

TECHNOLOGY

Autoinflammatory and autoimmune diseases root in dysbalances of the immune system. Our activated Treg are able to sustainably re-balance the system. They provide a curative treatment with a novel and highly efficient approach. We make our activated Treg significantly higher suppressive than non-activated Treg. Our lead product Actileucel is the first allogeneic Treg product that does not require any tissue matching: one product fits all.

WHO WE ARE

Our founders are industry experts and scientific pioneers in cell therapy. A spirit of collaboration and trust is the basis for our efficient development projects.

PIPELINE

We target autoinflammatory and autoimmune diseases with high unmet medical need such as GvHD and MS for which only limited treatment options exist. We accept the challenge to develop therapies that aim for prevention and curing instead of suppression of the immune system. Actileucel is currently being tested in a clinical phase Ib/II trial to prevent GvHD.

SPONSORSHIP

ActiTrexx is sponsored by a grant from the German Ministry of Education and Research

ActiTrexx is sponsored by the Innovationsfonds Rheinland-Pfalz II